The effects of hemodilution with Hemolink™ upon hemodynamics and blood flow distribution in anesthetized dogs

Hemoglobin based oxygen-carrying solutions (HBOCs) as hemoglobin replacement therapeutics are being tested for clinical use. Some of these products are associated with elevations in both systemic and pulmonary vascular resistances but their effect on the distribution of blood flow to major organs in larger animals have not been extensively described. We tested two formulations of o-raffinose cross-linked human hemoglobin, Hemolink(TM) (frozen Hemolink(TM)-1 and refrigerated Hemolink(TM)-2) and compared them to Pentaspan(R), a colloid volume expander in extensive clinical use. Cardiovascular measurements and the distribution of blood flow (radionuclide-labeled microspheres) to the major organs were detern-tined in Beagle dogs (n=5 per group). After baseline measurements, either Hernolink(TM)-1, or Hemolink(TM)-2, or Pentaspan(R) was exchange transfused in an isovolemic manner (resulting in hematocrit reduction to approximately 20-25%); measurements were made 30, 60, 120 and 180 min post-exchange. There was no significant difference in cardiac output, mean arterial pressures and systemic or pulmonary vascular resistance after exchange in any of the three groups. Myocardial blood flow increased in all three groups post-exchange but the increase was more sustained in the Hemolink(TM) groups. Endocardial/epicardial flow ratios were also maintained after exchange in all groups. Thus, Hemolink(TM) is ideally suited for volume replacement when used in conjunction with acute normovolemic hemodilution because under these circumstances, the adverse hemodynamic effects are alleviated while extra hemoglobin is added to the blood.